Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Study on the comparison between Bosentan and Macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: A randomized double-blinded non-inferiority parallel clinical trial.
Kashaki M, Mohazzab A, Radgoudarzi M, Bordbar A, Dabbagh S. Kashaki M, et al. Among authors: mohazzab a. Pediatr Neonatol. 2024 May 22:S1875-9572(24)00077-9. doi: 10.1016/j.pedneo.2023.12.007. Online ahead of print. Pediatr Neonatol. 2024. PMID: 38797632 Free article.
Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial.
Choobdar FA, Vahedi Z, Mazouri A, Torkaman M, Khosravi N, Khalesi N, Soltani Z, Mohazzab A, Ashkanipour R. Choobdar FA, et al. Among authors: mohazzab a. J Aerosol Med Pulm Drug Deliv. 2024 May 2. doi: 10.1089/jamp.2023.0043. Online ahead of print. J Aerosol Med Pulm Drug Deliv. 2024. PMID: 38687321
Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial.
Solaymani-Dodaran M, Kalantari S, Banihashemi SR, Es-Haghi A, Nofeli M, Mohazzab A, Mokhberalsafa L, Sadeghi F, Mokaram AR, Moradi MH, Razaz SH, Taghdiri M, Lotfi M, Setarehdan SA, Masoumi S, Ansarifar A, Ebrahimi S, Esmailzadehha N, Boluki Z, Khoramdad M, Molaipour L, Rabiei MH, Amiri FB, Filsoof S, Bani-Vaheb B, Derakhshani MR, Bayazidi S, Golmoradizadeh R, Shahsavan M, Safari S, Ghahremanzadeh N, Mohseni V, Erfanpoor S, Fallah Mehrabadi MH. Solaymani-Dodaran M, et al. Among authors: mohazzab a. Heliyon. 2024 Mar 3;10(5):e27370. doi: 10.1016/j.heliyon.2024.e27370. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463808 Free PMC article.
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
Erfanpoor S, Banihashemi SR, Mokhbaeralsafa L, Kalantari S, Es-Haghi A, Nofeli M, Rezaei Mokarram A, Sadeghi F, Hajimoradi M, Razaz SH, Taghdiri M, Lotfi M, Khorasani A, Ansarifar A, Masoumi S, Mohazzab A, Filsoof S, Mohseni V, Shahsavan M, Gharavi N, Setarehdan SA, Rabiee MH, Fallah Mehrabadi MH, Solaymani-Dodaran M. Erfanpoor S, et al. Among authors: mohazzab a. BMC Med. 2024 Feb 20;22(1):78. doi: 10.1186/s12916-024-03295-1. BMC Med. 2024. PMID: 38378570 Free PMC article. Clinical Trial.
Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial.
Mohazzab A, Fallah Mehrabadi MH, Es-Haghi A, Kalantari S, Mokhberalsafa L, Setarehdan SA, Sadeghi F, Rezaei Mokarram A, Haji Moradi M, Razaz SH, Taghdiri M, Ansarifar A, Lotfi M, Khorasani A, Nofeli M, Masoumi S, Boluki Z, Erfanpoor S, Bagheri Amiri F, Esmailzadehha N, Filsoof S, Mohseni V, Ghahremanzadeh N, Safari S, Shahsavan M, Bayazidi S, Raghami Derakhshani M, Rabiee MH, Golmoradi-Zadeh R, Khodadoost B, Solaymani-Dodaran M, Banihashemi SR. Mohazzab A, et al. J Pharm Sci. 2023 Dec;112(12):3012-3021. doi: 10.1016/j.xphs.2023.09.027. Epub 2023 Oct 11. J Pharm Sci. 2023. PMID: 37832918 Clinical Trial.
26 results